Modality
Vaccine
MOA
STINGag
Target
DLL3
Pathway
Neuroinflam
MMPSPALL
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
Jul 2023
→ Feb 2029
Phase 2Current
NCT06697603
1,617 pts·PSP
2023-07→2029-02·Completed
1,617 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-062.9y awayPh3 Readout· PSP
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Complet…
Catalysts
Ph3 Readout
2029-02-06 · 2.9y away
PSP
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06697603 | Phase 2/3 | PSP | Completed | 1617 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |